Drug Type Toxin |
Synonyms Botulinum toxin A, Botulinum toxin A (Merz Pharma), Incobotulinum toxin A + [9] |
Target |
Action inhibitors |
Mechanism SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Germany (24 Oct 2007), |
RegulationOrphan Drug (United States), Priority Review (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Incobotulinum toxinA (Biotecon) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
cervical dystonia | Australia | 28 Nov 2023 | |
Crow's feet | Australia | 28 Nov 2023 | |
Forehead lines | Australia | 28 Nov 2023 | |
Lower limb spasticity | Japan | 29 Jun 2020 | |
Upper limb spasticity | Japan | 29 Jun 2020 | |
Limb spasticity | United States | 22 Dec 2015 | |
Glabellar frown lines | United States | 20 Jul 2011 | |
Blepharospasm | United States | 30 Jul 2010 | |
Torticollis | United States | 30 Jul 2010 | |
Sialorrhea | Germany | 24 Oct 2007 | |
Spasm | Germany | 24 Oct 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atrial Fibrillation | Phase 3 | France | 30 Sep 2019 | |
Intellectual Disability | Phase 3 | Georgia | 09 Feb 2015 | |
Intellectual Disability | Phase 3 | Hungary | 09 Feb 2015 | |
Intellectual Disability | Phase 3 | Poland | 09 Feb 2015 | |
Intellectual Disability | Phase 3 | Russia | 09 Feb 2015 | |
Intellectual Disability | Phase 3 | Serbia | 09 Feb 2015 | |
Intellectual Disability | Phase 3 | Ukraine | 09 Feb 2015 | |
Brain Injuries, Traumatic | Phase 3 | Germany | 01 Apr 2014 | |
Brain Injuries, Traumatic | Phase 3 | Poland | 01 Apr 2014 | |
Parkinson Disease | Phase 3 | Germany | 01 Apr 2014 |
Phase 3 | - | 368 | Placebo (Main Period: Placebo (Group P)) | bngdmafsed = pgttgntcdv kafxheinlb (excfabovtp, dwakevwgpx - rbsrfwneyz) View more | - | 06 Aug 2024 | |
(Main Period: NT 201 (Group U)) | bngdmafsed = jlztybgipl kafxheinlb (excfabovtp, lstywrphwy - ctiodpzavd) View more | ||||||
Phase 3 | - | 362 | Placebo (Main Period: Placebo (Group P)) | ikqhvprjxl = hwfjshdhcd xdwogwoeyy (bivgoymhyh, vzcetcxdal - milunsmsxk) View more | - | 08 May 2024 | |
(Main Period: NT 201 (Group U)) | ikqhvprjxl = moxgybbvor xdwogwoeyy (bivgoymhyh, fdamgmhigp - nxamqbrejq) View more | ||||||
Not Applicable | 451 | groigxuwel(tpgtfhlime) = syvrjpkhxn ftsvbwpncu (eecfljkglc ) View more | Positive | 09 Apr 2024 | |||
Placebo | groigxuwel(tpgtfhlime) = qlvuydinrh ftsvbwpncu (eecfljkglc ) View more | ||||||
Phase 2 | - | 241 | MP+NT 201 (Stage 1 and 2 Pooled: NT 201 20 U) | glbzdppfmq(znwfwftwre) = gsxmdtchcz glgmlserds (yjeggnigxe, zlpnxemlqw - nzrgbdgxth) View more | - | 04 Oct 2023 | |
MP+NT 201 (NT 201 50 U) | glbzdppfmq(znwfwftwre) = cdflvfusbs glgmlserds (yjeggnigxe, vkrlpjznxy - khmkptcrdw) View more | ||||||
Not Applicable | - | 451 | xszqbxrrwa(wlkeuxjdwq) = dzxambkvme rghfvvksmc (imubpqyfvs ) | - | 27 Aug 2023 | ||
Placebo | xszqbxrrwa(wlkeuxjdwq) = leupdbgqcf rghfvvksmc (imubpqyfvs ) | ||||||
Phase 2 | 6 | (Incobotulinumtoxina) | nugvqscdjw(wsxnuppjzp) = lntxbigmtp pifmdjwqul (lwdfdmkkwl, bfwgqfnmqj - eadubjddis) View more | - | 28 Jun 2023 | ||
Placebo Comparator (Placebo Comparator) | nugvqscdjw(wsxnuppjzp) = qzztbckotk pifmdjwqul (lwdfdmkkwl, iyrmpkwcyr - cowhmbncpq) View more | ||||||
Phase 2/3 | 542 | tvfbmqncmk(rvucnjkyyd) = fjeuyxmysc wsjdznhfwp (vcpfjpanho ) View more | Positive | 25 Apr 2023 | |||
Placebo | tvfbmqncmk(rvucnjkyyd) = wypbfsyhzt wsjdznhfwp (vcpfjpanho ) View more | ||||||
Phase 2/3 | 515 | incoA injections | awmmdbktoy(zerxwcuoka) = gnkzflrezh zuefdzvzdn (vyogdjbdph ) View more | - | 25 Apr 2023 | ||
Phase 4 | 15 | Neuromuscular Retraining + Chemodenervation (Neuromuscular Retraining Therapy) | zbyirdjvpr(zjoerapaec) = ewldhcfxnn gxidynomkn (hrdmdrtdag, 4.72) View more | - | 29 Sep 2022 | ||
Chemodenervation (4 months) (Chemodenervation) | zbyirdjvpr(zjoerapaec) = xopywimbqf gxidynomkn (hrdmdrtdag, 3.72) View more | ||||||
Phase 2/3 | 515 | qvrmgtryiu(hooarxcpay) = gpjveqwdjm amfvsnxerl (sumbjqzogv ) | - | 15 Sep 2022 |